CG Oncology, Inc. (CGON)Healthcare | Biotechnology | Dallas, United States | NasdaqGS
72.50 USD
-2.74
(-3.642%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 72.55 +0.05 (0.069%) ⇧ (July 13, 2026, 7:15 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:03 a.m. EDT
CG Oncology is a high-volatility biotech play currently trading near its yearly peak, fueled by recent clinical milestones and revenue growth that outpaced estimates. Despite a strong analyst consensus and a robust balance sheet with over a billion dollars in cash against minimal debt, the company remains unprofitable with a valuation that stretches credibility. The recent price action suggests aggressive optimism, yet options flow shows a defensive undercurrent with significant put buying at lower strikes, hinting at fear of a correction. Without a dividend and with earnings still in the red, this is a speculative vehicle suitable only for investors comfortable with binary outcomes. The limited historical price data prevents a confident assessment of long-term stability, reinforcing the need to view this primarily as a short-term momentum trade rather than a core holding. |
| Model | MAE |
|---|---|
| MSTL_103 ✓ | 0.065952 |
| AutoARIMA | 0.071874 |
| AutoETS | 0.071875 |
| AutoTheta | 0.072519 |
| MSTL | 0.072625 |
Forecast horizon: 60 days | Selected: MSTL_103
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 6.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.649 |
| Excess Kurtosis | -0.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.694 |
| Revenue per Share | 0.064 |
| Market Cap | 6,394,679,296 |
| Forward P/E | -26.09 |
| Beta | 0.22 |
| Website | https://cgoncology.com |
As of July 11, 2026, 6:03 a.m. EDT: Call buyers are positioning for upside with significant open interest at 80-90 strikes, while put buyers are heavily hedging downside risk at 40-70 strikes. Implied volatility is elevated across expirations.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9050193 |
| Address1 | 3,000 Pegasus Park Drive |
| Address2 | Suite 1640 |
| All Time High | 77.0 |
| All Time Low | 14.8 |
| Ask | 91.39 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 1,397,360 |
| Average Daily Volume3 Month | 1,069,640 |
| Average Volume | 1,069,640 |
| Average Volume10Days | 1,397,360 |
| Beta | 0.219 |
| Bid | 53.42 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 12.405 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 72.5 |
| Current Ratio | 31.297 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 74.75 |
| Day Low | 70.715 |
| Debt To Equity | 0.694 |
| Display Name | CG Oncology |
| Earnings Timestamp | 1,778,243,400 |
| Earnings Timestamp End | 1,786,105,800 |
| Earnings Timestamp Start | 1,786,105,800 |
| Ebitda | -212,696,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -25.04 |
| Enterprise To Revenue | 1,050.288 |
| Enterprise Value | 5,326,012,416 |
| Eps Current Year | -2.65514 |
| Eps Forward | -2.77916 |
| Eps Trailing Twelve Months | -2.34 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 64.9742 |
| Fifty Day Average Change | 7.5258026 |
| Fifty Day Average Change Percent | 0.11582756 |
| Fifty Two Week Change Percent | 190.50192 |
| Fifty Two Week High | 77.0 |
| Fifty Two Week High Change | -4.5 |
| Fifty Two Week High Change Percent | -0.058441557 |
| Fifty Two Week Low | 23.65 |
| Fifty Two Week Low Change | 48.85 |
| Fifty Two Week Low Change Percent | 2.0655391 |
| Fifty Two Week Range | 23.65 - 77.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,706,193,000,000 |
| Float Shares | 65,823,742 |
| Forward Eps | -2.77916 |
| Forward P E | -26.087019 |
| Free Cashflow | -105,890,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 142 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -135,442,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00229 |
| Held Percent Institutions | 1.09902 |
| Implied Shares Outstanding | 88,202,473 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-01-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas. |
| Long Name | CG Oncology, Inc. |
| Market | us_market |
| Market Cap | 6,394,679,296 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_115902660 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -186,744,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,636,354,068 |
| Number Of Analyst Opinions | 14 |
| Open | 74.75 |
| Operating Cashflow | -160,012,000 |
| Operating Margins | -61.30102 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 949 409 3700 |
| Post Market Change | 0.05000305 |
| Post Market Change Percent | 0.06896973 |
| Post Market Price | 72.55 |
| Post Market Time | 1,783,984,526 |
| Previous Close | 75.24 |
| Price Eps Current Year | -27.305529 |
| Price Hint | 2 |
| Price To Book | 5.8444176 |
| Price To Sales Trailing12 Months | 1,261.0293 |
| Profit Margins | 0.0 |
| Quick Ratio | 30.597 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.375 |
| Region | US |
| Regular Market Change | -2.74 |
| Regular Market Change Percent | -3.64168 |
| Regular Market Day High | 74.75 |
| Regular Market Day Low | 70.715 |
| Regular Market Day Range | 70.715 - 74.75 |
| Regular Market Open | 74.75 |
| Regular Market Previous Close | 75.24 |
| Regular Market Price | 72.5 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 985,784 |
| Return On Assets | -0.14419 |
| Return On Equity | -0.20788999 |
| Revenue Growth | 19.827 |
| Revenue Per Share | 0.064 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 88,202,473 |
| Shares Percent Shares Out | 0.1368 |
| Shares Short | 12,068,774 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 9,810,951 |
| Short Name | CG Oncology, Inc. |
| Short Percent Of Float | 0.1393 |
| Short Ratio | 9.67 |
| Source Interval | 15 |
| State | TX |
| Symbol | CGON |
| Target High Price | 108.0 |
| Target Low Price | 80.0 |
| Target Mean Price | 90.28571 |
| Target Median Price | 88.5 |
| Total Cash | 1,076,242,048 |
| Total Cash Per Share | 12.202 |
| Total Debt | 7,575,000 |
| Total Revenue | 5,071,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 54.411224 |
| Two Hundred Day Average Change | 18.088776 |
| Two Hundred Day Average Change Percent | 0.33244565 |
| Type Disp | Equity |
| Volume | 985,784 |
| Website | https://cgoncology.com |
| Zip | 75,247 |